CFM
CTNM

Cornerstone Financial Management’s Contineum Therapeutics CTNM Stock Holding History

Cornerstone Financial Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Hold
64
– – ﹤0.01% 1086
2026
Q1 		$836 Hold
64
– – ﹤0.01% 1032
2025
Q4 		$732 Buy
+64
New +$730 ﹤0.01% 1034

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cornerstone Financial Management's CTNM Position: Q2 2026 in Review

Cornerstone Financial Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 64 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Cornerstone Financial Management first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Cornerstone Financial Management held 64 shares of Contineum Therapeutics worth $1.05K as of Q2 2026.
  • Cornerstone Financial Management left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1086 holding.
  • Cornerstone Financial Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.